Wells Fargo Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
Wells Fargo Keeps Their Buy Rating on Eli Lilly & Co (LLY)
J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Goldman Sachs Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $888
Eli Lilly Analyst Ratings
HSBC Downgrades Eli Lilly and Co(LLY.US) to Sell Rating, Cuts Target Price to $700
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Announces Target Price $1,000
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
A Quick Look at Today's Ratings for Eli Lilly and Co(LLY.US), With a Forecast Between $975 to $1,124
Cantor Fitzgerald Initiates Coverage On Eli Lilly With Overweight Rating, Announces Price Target of $975
Eli Lilly Analyst Ratings
J.P. Morgan Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Leerink Partners Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Raises Target Price to $989
BMO Capital Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $900
Bernstein Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Maintains Target Price $1,100
Guggenheim Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $928
Eli Lilly Analyst Ratings
Morgan Stanley Maintains Eli Lilly and Co(LLY.US) With Buy Rating, Cuts Target Price to $1,124
BofA Securities Maintains Eli Lilly and Co(LLY.US) With Buy Rating
Eli Lilly Is Maintained at Overweight by Morgan Stanley